Lv51
1580 积分 2024-05-14 加入
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
29天前
已完结
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
29天前
已完结
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
1个月前
已完结
Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial
2个月前
已完结
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
2个月前
已完结
The sequence of changes in intravascular imaging findings during lipid-lowering therapy and its implication
3个月前
已完结
Indirect comparison of statin–ezetimibe and statin–PCSK9 inhibitor combination therapies for coronary artery plaque regression in acute coronary syndrome
3个月前
已完结
Assessing Children's Blood Pressure—Considerations of Age and Body Size: The Muscatine Study
7个月前
已完结
Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis
8个月前
已关闭
PSCK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis
8个月前
已完结
皖公网安备34019202002308
